Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070122 | 1.00 | TSHR (0.51) | TSHRMMP12MMP2MMP9MMP13 | |
| SCHEMBL2478370 | 0.81 | TSHR (0.54) | TSHRMMP12MMP2MMP9MMP13 | |
| SCHEMBL26837610 | 0.81 | TSHR (0.54) | TSHRMMP12MMP2MMP9MMP13 | |
| SCHEMBL5513603 | 0.81 | CPA1 (0.56) | NPC1RAB9ACPA1CPB1CPA3 | |
| SCHEMBL4439360 | 0.81 | TSHR (0.54) | TSHRMMP12MMP2MMP9MMP13 | |
| SCHEMBL22556247 | 0.81 | CPA1 (0.56) | NPC1RAB9ACPA1CPB1CPA3 | |
| SCHEMBL7712795 | 0.81 | SMN1; SMN2 (0.53) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL14544335 | 0.80 | CTSK (0.45) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL10188354 | 0.79 | TRPA1 (0.52) | TSHRSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL18065715 | 0.77 | MMP12 (0.56) | TSHRMMP12MMP2MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| EP-1773853-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | Sumitomo Chemical Company, Limited (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121157-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | TSHR 2115/4885MMP12 3968/4885MMP2 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.